Source link : https://www.newshealth.biz/health-news/icodec-semaglutide-combo-shows-benefit-in-type-2-diabetes/
MADRID — Novo Nordisk’s investigational once-weekly combination of insulin icodec plus semaglutide (IcoSema) could benefit people with type 2 diabetes who don’t reach target glycemic goals with either single agent alone, new research suggests. Data for three 52-week multicenter randomized open-label trials from the company’s phase 3a COMBINE program were presented on September 11, 2024, […]
Author : News Health
Publish date : 2024-09-12 13:24:39
Copyright for syndicated content belongs to the linked Source.
Categories